4 Citations (Scopus)
24 Downloads (Pure)


Ocriplasmin is used to treat vitreomacular traction (VMT), with or without full-thickness macular hole (MH). We systematically reviewed the evidence on ocriplasmin's effect on vitreomacular adhesion resolution (VMAR), MH closure, vitrectomy, and best-corrected visual acuity (BCVA) and investigated the effect of baseline covariates on outcome. We applied individual participant data meta-analyses to the entire population and to subgroups defined by MH or epiretinal membrane (ERM) presence. Safety data were pooled and tabulated. Five randomized controlled trials (1067 participants) were included. Six months after treatment, ocriplasmin achieved higher rates of VMAR and MH closure versus control, lowered vitrectomy odds and increased the likelihood of a ≥10-letter BCVA increase. VMAR rates were lower when ERM, broad VMA (>1500 µm), diabetic retinopathy, or pseudophakia were present and higher in younger participants, women, and eyes with MHs. Ocriplasmin-treated participants experienced more short-term visual impairment that was not predictive of final BCVA, as well as vitreous floaters, photopsia, photophobia, eye pain, blurred vision, and dyschromatopsia. The most common serious adverse events for ocriplasmin and control, respectively, were MH progression (22.5%, 17.3%), new MH (1.5%, 3.4%) and retinal detachment (0.8%, 1.2%). Ocriplasmin promotes VMAR and MH closure. Transient visual phenomena are not uncommon.

Original languageEnglish
JournalSurvey of Ophthalmology
Publication statusE-pub ahead of print - 1 Sept 2021


Dive into the research topics of 'Ocriplasmin for Treatment of Vitreomacular Traction and Macular Hole: A Systematic Literature Review and Individual Participant Data Meta-Analysis of Randomized, Controlled, Double-Masked Trials'. Together they form a unique fingerprint.

Cite this